… Creatinine clearance (CrCl) was calculated using a lean body weight estimate formula in
the Cockcroft–Gault equation based on its performance in morbid obesity [20]. …

… currently used piperacillin/tazobactam dosing regimens in obese and nonobese patients. For
… I Standard body weight, II lower BMI threshold for morbid obesity, III healthy renal function […

… BMI groups (Fig. 5). Our data do not support that an increase in renal clearance accounts
for elevated CL PIP in morbidly obese patients… in obese patients [50, 51] may impose dosing …

… and piperacillin-tazobactam for obese and non-obese patients with Enterobacteriaceae
bacteremia. Obese patients … This optimized dosing, coupled with the relatively low median MIC …

… (35) Most (80%) patients received extendedinfusion piperacillin/tazobactam (3.375gq 8 hours
… non-obese, obese, and morbidly obese patients and that weight alone should not prompt …

… dosing of piperacillin-tazobactam is suboptimal for patients in … of piperacillin-tazobactam
popPK models is currently available. As the amount of information on piperacillin-tazobactam …

… Piperacillin-tazobactam dosing overseen by clinical pharmacy practitioners were adjusted
as necessary based on renal function and indication per discussion with the primary admitting …

… Piperacillin-tazobactam is commonly used in neutropenic sepsis at standard doses that do
not … (PK/PD) targets in patients receiving piperacillin/tazobactam therapy and to evaluate the …

… In conclusion, the findings recommend dosing of piperacillin-tazobactam with the aim of
achieving a pharmacodynamic target %fT >MIC of at least 60% in these patients. …

… piperacillin–tazobactam therapy ≤ 72 h before inclusion, and were managed with a central
venous and/or arterial catheter. Patients … Dose and duration of piperacillin–tazobactam were …